139 related articles for article (PubMed ID: 34144176)
21. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
22. HPV vaccine introduction and implementation in Low- and Middle-Income Countries.
Denny L
Vaccine; 2022 Mar; 40 Suppl 1():A1. PubMed ID: 35246312
[No Abstract] [Full Text] [Related]
23. Worldwide impact of the human papillomavirus vaccine.
Hakim AA; Dinh TA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):44-53. PubMed ID: 19387841
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
25. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.
Ochalek J; Abbas K; Claxton K; Jit M; Lomas J
BMJ Glob Health; 2020 Oct; 5(10):. PubMed ID: 33082132
[TBL] [Abstract][Full Text] [Related]
26. Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine.
Zhou X; Sun L; Yao X; Li G; Wang Y; Lin Y
Front Immunol; 2020; 11():1434. PubMed ID: 32754157
[TBL] [Abstract][Full Text] [Related]
27. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
28. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.
Bruni L; Saura-Lázaro A; Montoliu A; Brotons M; Alemany L; Diallo MS; Afsar OZ; LaMontagne DS; Mosina L; Contreras M; Velandia-González M; Pastore R; Gacic-Dobo M; Bloem P
Prev Med; 2021 Mar; 144():106399. PubMed ID: 33388322
[TBL] [Abstract][Full Text] [Related]
29. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
30. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
31. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Maver PJ; Poljak M
Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
33. Vaccination against human papillomavirus.
Mello CF
Einstein (Sao Paulo); 2013 Dec; 11(4):547-9. PubMed ID: 24488402
[TBL] [Abstract][Full Text] [Related]
34. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women?
Liu X; Feng A; Cui Y; Tobe RG
Biosci Trends; 2013 Aug; 7(4):159-67. PubMed ID: 24056165
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
[TBL] [Abstract][Full Text] [Related]
36. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
37. Cervical Cancer Prevention in Low- and Middle-Income Countries.
Allanson ER; Schmeler KM
Clin Obstet Gynecol; 2021 Sep; 64(3):501-518. PubMed ID: 34120126
[TBL] [Abstract][Full Text] [Related]
38. Lessons learned from domestic and international human papillomavirus vaccination programs: a review.
Miller K; Dilley SE; Huh WK
Am J Obstet Gynecol; 2018 May; 218(5):467-473. PubMed ID: 28888586
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus vaccine disease impact beyond expectations.
de Sanjose S; Brotons M; LaMontagne DS; Bruni L
Curr Opin Virol; 2019 Dec; 39():16-22. PubMed ID: 31382121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
